de Bruin, I.J.A. http://orcid.org/0000-0002-5776-4971
Wyers, C.E. http://orcid.org/0000-0001-7662-3990
Souverein, P.C. http://orcid.org/0000-0002-7452-0477
van Staa, T.P. http://orcid.org/0000-0001-9363-742X
Geusens, P.P.M.M. http://orcid.org/0000-0002-7547-9146
van den Bergh, J.P.W. http://orcid.org/0000-0003-3984-2232
de Vries, F. http://orcid.org/0000-0003-3837-8319
Driessen, J.H.M. http://orcid.org/0000-0002-4503-6408
Funding for this research was provided by:
Utrecht University
Article History
Received: 15 November 2019
Accepted: 14 February 2020
First Online: 7 April 2020
Compliance with ethical standards
:
: Dr. Wyers, Dr. Souverein, Dr. van Staa and Dr. Driessen have nothing to disclose.Dr. de Bruin reports personal fees from Pfizer, personal fees from Novartis, personal fees from Sanofi, outside the submitted work; Dr. van den Bergh reports grants and personal fees from Amgen, grants and personal fees from Eli Lilly, personal fees from UCB, outside the submitted work; Dr. Geusens reports grants and personal fees from Amgen, grants from Pfizer, grants from MSD, grants from UCB, grants from Abbott, grants and personal fees from Lilly, grants from BMS, grants from Novartis, grants from Roche, grants from Will Pharma, outside the submitted work; Dr. de Vries supervises various PhD students who are employed with F. Hoffmann la Roche Ltd. (Welwyn Garden City UK and Basel, Switzerland). The topics of their PhDs are not related to the current work. Dr. de Vries has not received any fees or reimbursements for this.
: Ethical approval by the institutional or national research ethics committee was not required.For this type of study, formal consent is not required.